# Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
Canonical URL: https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-planned-leadership-transition-for-steve-kelsey-m-d
Ticker: RVMD
Company: Revolution Medicines
Source: Revolution Medicines
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.revmed.com
## Summary

Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.

## Article Body
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.
## Recent Company News
- 2026-07-02 12:00 EST — [Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026](https://biopharmsignal.com/news/RVMD/revolution-medicines-presents-phase-1-2-clinical-data-for-zoldonrasib-combinatio-b6abe879) — Source: Revolution Medicines
- 2026-06-25 13:46 EST — [Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026](https://biopharmsignal.com/news/RVMD/revolution-medicines-to-present-clinical-data-from-ras-on-inhibitor-combination-trials-in-pancreatic-cancer-at-esmo-gastrointestinal-cancers-congress-2026) — Source: Revolution Medicines
- 2026-06-25 13:46 EST — [Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-begins-treating-patients-in-rasolute-305-a-phase-3-clinical-trial-evaluating-zoldonrasib-in-combination-with-chemotherapy-as-a-first-line-treatment-for-patients-with-ras-g12d-metastatic-pancreatic-cancer) — Source: Revolution Medicines
- 2026-06-25 13:46 EST — [Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.](https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-planned-leadership-transition-for-steve-kelsey-m-d) — Source: Revolution Medicines
- 2026-06-25 13:46 EST — [Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-asco-plenary-presentation-highlighting-unprecedented-results-from-pivotal-phase-3-rasolute-302-clinical-trial-of-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer) — Source: Revolution Medicines
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)